33,576 Shares in Lifevantage Corporation (NASDAQ:LFVN) Acquired by Calamos Advisors LLC

Calamos Advisors LLC bought a new stake in Lifevantage Corporation (NASDAQ:LFVN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 33,576 shares of the company's stock, valued at approximately $490,000. Calamos Advisors LLC owned 0.27% of Lifevantage as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Hillsdale Investment Management Inc. lifted its holdings in Lifevantage by 7.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company's stock valued at $258,000 after buying an additional 1,000 shares during the period. Barclays PLC raised its holdings in shares of Lifevantage by 3.6% during the fourth quarter. Barclays PLC now owns 43,472 shares of the company's stock valued at $763,000 after purchasing an additional 1,506 shares during the period. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Lifevantage by 23.2% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company's stock valued at $188,000 after purchasing an additional 2,421 shares during the period. Northern Trust Corp raised its holdings in shares of Lifevantage by 27.6% during the fourth quarter. Northern Trust Corp now owns 44,176 shares of the company's stock valued at $774,000 after purchasing an additional 9,552 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new position in shares of Lifevantage during the first quarter valued at about $156,000. Institutional investors and hedge funds own 35.32% of the company's stock.

Insider Buying and Selling

In other news, CFO Carl Aure sold 2,746 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.39, for a total transaction of $36,768.94. Following the completion of the sale, the chief financial officer owned 133,303 shares in the company, valued at $1,784,927.17. This trade represents a 2.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 20.65% of the company's stock.

Lifevantage Stock Performance

Shares of NASDAQ LFVN traded down $0.69 during trading on Thursday, hitting $12.37. 105,423 shares of the company traded hands, compared to its average volume of 214,933. The business's fifty day moving average is $12.64 and its 200 day moving average is $15.85. Lifevantage Corporation has a fifty-two week low of $5.76 and a fifty-two week high of $27.38. The firm has a market capitalization of $155.74 million, a price-to-earnings ratio of 17.93 and a beta of 0.43.

Lifevantage (NASDAQ:LFVN - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Lifevantage had a net margin of 4.12% and a return on equity of 34.67%. The company had revenue of $58.44 million for the quarter, compared to analyst estimates of $60.99 million.

Lifevantage Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 30th were paid a $0.045 dividend. This is a positive change from Lifevantage's previous quarterly dividend of $0.04. The ex-dividend date was Friday, May 30th. This represents a $0.18 annualized dividend and a yield of 1.46%. Lifevantage's dividend payout ratio (DPR) is 26.09%.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.